Ravgen owns U.S. Patent Nos. 7,727,720 and 7,332,277, covering methods to detect cell-free fetal DNA from the mother’s blood. Ravgen said the patented technology can be used to replace conventional, invasive prenatal testing for genetic disorders.
The company sued Natera and PerkinElmer in June for allegedly infringing the same two patents.
Laboratory Corporation of America’s MaterniT and InformaSeq prenatal DNA tests and ctDx Lung Assay test for lung cancer patients infringe the patents, Ravgen says. ...